GlucoTrack Net Worth
GlucoTrack Net Worth Breakdown | GCTK |
GlucoTrack Net Worth Analysis
GlucoTrack's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including GlucoTrack's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of GlucoTrack's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform GlucoTrack's net worth analysis. One common approach is to calculate GlucoTrack's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares GlucoTrack's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing GlucoTrack's net worth. This approach calculates the present value of GlucoTrack's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of GlucoTrack's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate GlucoTrack's net worth. This involves comparing GlucoTrack's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into GlucoTrack's net worth relative to its peers.
Enterprise Value |
|
To determine if GlucoTrack is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding GlucoTrack's net worth research are outlined below:
| GlucoTrack generated a negative expected return over the last 90 days | |
| GlucoTrack has high historical volatility and very poor performance | |
| GlucoTrack has some characteristics of a very speculative penny stock | |
| GlucoTrack has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (7.1 M) with loss before overhead, payroll, taxes, and interest of (20 K). | |
| GlucoTrack currently holds about 3.85 M in cash with (6.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.25, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| GlucoTrack has a frail financial position based on the latest SEC disclosures | |
| Roughly 35.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: GlucoTrack, Inc. Closes Offering and Private Placement, Holding Special Meeting for Stockholder Approval |
GlucoTrack uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in GlucoTrack. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to GlucoTrack's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know GlucoTrack's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as GlucoTrack is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GlucoTrack backward and forwards among themselves. GlucoTrack's institutional investor refers to the entity that pools money to purchase GlucoTrack's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 27.2 K | Alerus Financial Na | 2024-09-30 | 13.9 K | Cetera Investment Advisers | 2024-06-30 | 10 K | Ubs Group Ag | 2024-06-30 | 6.1 K | Renaissance Technologies Corp | 2024-06-30 | 0.0 | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Sabby Management Llc | 2024-06-30 | 0.0 | Accurate Wealth Management, Llc | 2024-06-30 | 0.0 | Virtue Capital Management, Llc | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 |
Follow GlucoTrack's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.04 M.Market Cap |
|
Project GlucoTrack's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.45) | (1.52) | |
| Return On Capital Employed | (2.09) | (1.99) | |
| Return On Assets | (1.45) | (1.52) | |
| Return On Equity | (2.22) | (2.11) |
When accessing GlucoTrack's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures GlucoTrack's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of GlucoTrack's profitability and make more informed investment decisions.
Evaluate GlucoTrack's management efficiency
GlucoTrack has return on total asset (ROA) of (1.575) % which means that it has lost $1.575 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.4113) %, meaning that it created substantial loss on money invested by shareholders. GlucoTrack's management efficiency ratios could be used to measure how well GlucoTrack manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -1.52. Return On Capital Employed is expected to rise to -1.99 this year. At this time, GlucoTrack's Total Current Liabilities is quite stable compared to the past year. Change To Liabilities is expected to rise to about 69.9 K this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 3.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.77 | 0.81 | |
| Tangible Book Value Per Share | 0.77 | 0.81 | |
| Enterprise Value Over EBITDA | (0.16) | (0.17) | |
| Price Book Value Ratio | 1.70 | 1.79 | |
| Enterprise Value Multiple | (0.16) | (0.17) | |
| Price Fair Value | 1.70 | 1.79 | |
| Enterprise Value | 1 M | 977.4 K |
Understanding the operational decisions made by GlucoTrack management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Return On Equity (5.41) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GlucoTrack insiders, such as employees or executives, is commonly permitted as long as it does not rely on GlucoTrack's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases GlucoTrack insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Darivoff Philip over a month ago Discretionary transaction by Darivoff Philip of tradable shares of GlucoTrack at 5.8 subject to Rule 16b-3 | ||
Paul Goode over three months ago Acquisition by Paul Goode of 42000 shares of GlucoTrack at 4.95 subject to Rule 16b-3 | ||
Darivoff Philip over six months ago Discretionary transaction by Darivoff Philip of tradable shares of GlucoTrack at 5.8 subject to Rule 16b-3 | ||
Darivoff Philip over six months ago Discretionary transaction by Darivoff Philip of tradable shares of GlucoTrack subject to Rule 16b-3 | ||
Seff Leslie over six months ago Acquisition by Seff Leslie of 22727 shares of GlucoTrack at 1.98 subject to Rule 16b-3 |
GlucoTrack Earnings per Share Projection vs Actual
GlucoTrack Corporate Management
| Erez BenZvi | GM Product | Profile | |
| Drinda Benjamin | Vice Marketing | Profile | |
| Paul Goode | Chief Officer | Profile | |
| MScEE MBA | Chairman CoFounder | Profile | |
| Mark Tapsak | Vice Technology | Profile | |
| Esq CPA | Chief Officer | Profile | |
| David BA | CoFounder | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlucoTrack. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlucoTrack. If investors know GlucoTrack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlucoTrack listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.91) | Return On Assets (1.57) | Return On Equity (5.41) |
The market value of GlucoTrack is measured differently than its book value, which is the value of GlucoTrack that is recorded on the company's balance sheet. Investors also form their own opinion of GlucoTrack's value that differs from its market value or its book value, called intrinsic value, which is GlucoTrack's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlucoTrack's market value can be influenced by many factors that don't directly affect GlucoTrack's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlucoTrack's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlucoTrack is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlucoTrack's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.